Mbx biosciences reports second quarter 2025 financial results and recent corporate highlights

Topline results for the phase 2 avail™ trial of canvuparatide in hypoparathyroidism on track for q3 2025 imapextide (mbx 1416) phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in q3 2025 mbx 4291 phase 1 trial initiation in obesity anticipated in q3 2025 $224.9 million in cash, cash equivalents and marketable securities as of june 30, 2025; expected to support operations into mid-2027 carmel, ind., aug. 07, 2025 (globe newswire) -- mbx biosciences, inc. (nasdaq: mbx), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the second quarter ended june 30, 2025, and highlighted recent corporate progress.
MBX Ratings Summary
MBX Quant Ranking